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This review is intended to provide an overview of tissue engineering 
strategies using scaffold biomaterials to develop a vascularized tissue engineered 
construct for nano-pathophysiology. Two primary topics are discussed. The first is the 
biological or synthetic microenvironments that regulate cell behaviors in pathological 
conditions and tissue regeneration. Second is the use of scaffold biomaterials with 
angiogenic factors and/or cells to realize vascularized tissue engineered constructs for 
nano-pathophysiology. These topics are significantly overlapped in terms of 
three-dimensional (3-D) geometry of cells and blood vessels. Therefore, this review 
focuses on neovascularization of 3-D scaffold biomaterials induced by angiogenic 
factors and/or cells. The novel strategy of this approach in nano-pathophysiology is to 
utilize the vascularized tissue engineered construct as a tissue model to predict the 
distribution and subsequent therapeutic efficacy of a drug delivery system with different 
physicochemical and biological properties.  
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In the body, cells and tissue are organized into three-dimensional (3-D) 
architecture. To engineer such functional tissues, scaffold biomaterials have to be 
fabricated through different methodologies that facilitate cell distribution and guide 
growth into a 3-D space. Traditional static two-dimensional (2-D) cell culture systems 
allow us to understand many complex biological processes in a homogeneous 
population of cells. However, in the native physiological system, cells exist in a 
complex microenvironment consisting of various biological cues, such as signaling 
molecules, extracellular matrix (ECM) molecules, biomechanical forces, and cell–cell 
interactions [1]. Although the simplicity of the 2-D culture systems can elucidate 
individual cell phenomena, the 2-D culture systems reduces the biological importance 
and complexity of dynamic tissue architectures that affect the physiological behavior of 
cells in vivo. For instance, unlike in 2-D culture, mammary epithelial cells embedded in 
a 3-D environment stop growing, form acinar structures, and establish a de novo 
basement membrane [2-4]. For this reason, 3-D tissue constructs better reflect native 
biophysical and biochemical environments, and hence have become a focus of recent 
investigation [5].  
In addition to the geometric effect, the microenvironment plays a pivotal role 
in regulating the spatial distribution of nutrients, oxygen, and soluble signaling 
molecules, such as growth factors, hormones, and cytokines. These chemical gradients 
are essential for the regulation of fundamental cell processes, such as cell migration [6], 
angiogenesis [7, 8], and tissue patterning in development [9-12]. This spatial 
distribution of diffusible factors is complex and is affected by the surrounding ECM, the 
organization of vasculature, and distribution of neighboring cells. Furthermore, the 
sustained presence of a 3-D concentration gradient is required to elicit chemotactic 
events such as cell migration and polarization. However, under conventional 2-D 
culture conditions, cell-secreted or exogenously added soluble factors diffuse 
ubiquitously throughout the medium, thereby forming a rapid equilibrium devoid of 
these gradients. 
Similar to the signaling molecule, the diffusion of soluble therapeutic drugs, 
which is one of the important determinants in the therapeutic efficacy of the drug, is 
regulated by microenvironmental properties including oxygen concentration, vascular 
structure, local pH, and inner pressure in pathological tissues [13]. For instance, Kano et 
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al. demonstrated that the efficacy of anticancer drug-incorporated nanoparticles with a 
diameter of several tens of nanometer was largely determined by the structure of 
vascular walls [14]. In order to act effectively to the cancer cells, these nanoparticles 
must pass through the vascular wall towards the interstitial tissue [14-17]. By depleting 
alpha smooth muscle actin (αSMA) positive cells from the tumor vasculature with an 
inhibitor of transforming growth factor (TGF)-β receptor type I, the resistance to the 
anticancer drug in a model of pancreatic cancer is diminished, and thus alteration of the 
tumor microenvironment enhances the therapeutic efficacy of the anticancer drug even 
in the intractable tumor. This environmental effect in the cancer treatment is not 
predictable by the conventional drug screening based on the regular 2-D culture, where 
cancer cells derived from the intractable tumor are always sufficiently sensitive to 
conventional anticancer drugs. 
Normal blood vessels and tumor-induced blood vessels differ greatly in 
morphology and function. Normal blood vessels recruit pericytes and vascular smooth 
muscle cells to the endothelial cells (ECs) to stabilize the vessels. Depending on the 
type of tumor, tumor-induced blood vessels can be either less stable, disorganized, and 
leaky, or conversely, less leaky with increased pericyte-coverage and collagen 
deposition [16, 17]. The leakiness of the tumor vasculature leads to the increased 
accumulation of nanoparticles depending on their size, a phenomenon which has been 
called the “enhanced permeability and retention (EPR) effect” that could enhance the 
efficacy of the treatment with a less adverse effect [18, 19]. On the contrary, it is likely 
that tumor vasculature that has increased pericyte-coverage and collagen deposition will 
impair the permeation of the nanoparticle. Taken together, the complexity of the tumor 
vasculature requires the consideration of multiple confounding factors in determining 
drug efficacy, some of which may be better evaluated with interdisciplinary approaches 
between engineering and basic clinical medicine.  
Quantitative understanding of how the number of the pericyte layer and 
thickness of the collagen deposition affect the penetration, accumulation, and efficacy 
of nanoparticles plays a pivotal role in developing nanotherapeutics for intractable 
tumors. However, the lack of the reproducibility and standardization of conventional 
animal models, such as tumor zenograft models, is a major drawback to tackle the issue. 
One interdisciplinary approach to accurately mimic a nano-pathophysiological 
microenvironment in tumors is to create vascularized tissue engineered constructs with 
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particular vascular structures seen in pathological tissues by utilizing scaffold 
biomaterials and following controlled positioning of different cells therein. There are 
two strategies to create vascularized tissue engineered constructs (Figure 1). The first is 
“top down approach” based on the ECs and their ability to form vascular networks in 
vivo. The second strategy, “bottom-up approach”, deals with the vessels themselves in 
vitro. In these approaches, scaffold biomaterials function not only as a 3-D template for 
cell attachment, cell positioning, ECM presentation, and subsequent tissue formation, 
but also as a spatio-temporally controlled delivery system of angiogenic factors and/or 
cells. We will now explore these scaffold biomaterials and their use as controlled 
delivery systems of angiogenic factors and/or cells, and review how angiogenic growth 
factors and/or cells play an integral role in introducing vascular networks into tissue 
engineered constructs. We also discuss how this knowledge might inspire the 
development of novel vascularized tissue engineered constructs for 
nano-pathophysiology in the future. 
 
2. Scaffold biomaterials for tissue fabrication 
Scaffold biomaterials have been extensively investigated as a 3-D template 
for cell attachment and subsequent tissue formation. Unlike conventional 2-D cultures, 
which involve growing cells in a non-physiological 2-D environment, positioning of 
cells within 3-D scaffolds may provide more natural microenvironments that enable 
cells to promote physiological functions in vitro [5, 20-23]. On the contrary, it has been 
demonstrated that fibroblasts and surrounding cells are regulated by pathological ECM 
proteins in fibrosis and tumor [24-28]. In addition to the interactions between the cells 
and the ECM, the mechanical properties of the substrate (i.e., stromal tissues) also 
regulate multiple cellular processes, and thus have numerous effects on tissue 
development and disease processes [29-31]. Indeed, mimicking such natural 
microenvironments seems to be a promising strategy to design scaffold biomaterials. 
However, there still remain some substantial challenges to create natural 
microenvironment-mimicking scaffold biomaterials. One possible way to tackle this 
issue is to encourage cells to create their own ECM microenvironments in scaffold 
biomaterials. Thus, design of scaffold biomaterials facilitating cell secretion of 
pathological ECM proteins therein or an appropriate combination of 
biological/biophysical cues, such as ECM structures, stiffness, and mechanical stimuli, 
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may modify cell activities in tissue engineered constructs with the pathological 
microenvironment.  
 
2.1. Biological/biophysical cues 
Several biological/biophysical cues, such as ECM structures, stiffness, and 
mechanical stimuli, may modify cell activities in scaffold biomaterials. By utilizing 
such cues, people could expect cell secretion of ECM proteins therein and following 
tissue formation similar to pathological tissues. Among them, the ECM that forms the 
structural framework of tissues is one of the major contributors to the development of a 
unique microenvironment [32]. Fibroblasts are one of the abundant cell types that 
secrete ECM in connective tissues [33]. Under pathological conditions, alteration in 
cytokine secretion patterns activates fibroblasts, such as myofibroblasts and cancer 
associated fibroblasts (CAF), which secrete a different composition of ECM proteins in 
stromal tissues when compared to their healthy counterparts [26-28] (Table 1). In tumor 
tissues, several ECM proteins, such as tenasin-C (TNC), fibronectin (FN), and SPARC 
(secreted protein, acidic and rich in cysteine), are considerably up-regulated, and some 
of them exists as alternatively spliced isoforms that promote tumor growth and invasion 
[34-47]. For instance, fibroblast expression of caveolin-1 in vitro and in vivo favors an 
tumor-specific organized 3-D stromal architecture of fibrin matrices that promotes 
spindle morphology, facilitates tumor cell invasion, and increases p190-dependent 
metastatic potency [48]. Moreover, DeQuach et al. developed naturally derived ECM 
coatings for cell culture that provide important tissue-specific cues unlike traditional 
cell culture coatings, thereby enabling the maturation of committed C2C12 skeletal 
myoblast progenitors and human embryonic stem cells (hESCs) differentiated into 
cardiomyocytes [49]. Taken together, it is possible that coating of pathological ECM 
proteins may provide better microenvironments for disease cells to create tissue 
engineered constructs with the pathological microenvironment.  
In addition to the interactions between the cells and the ECM, the mechanical 
properties of the substrate (i.e., stromal tissues) also regulate multiple cellular processes, 
and thus have numerous effects on tissue development and disease processes [29-31]. 
Stiffness of a substrate, measured by the Young’s modulus, plays an important role in 
the adherence of the anchorage-dependent cells [1, 50]. Soft tissue has a low Young’s 
modulus (0.5-2 kPa). Normal mammary tissues are quite soft (0.15 kPa), while this low 
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stiffness shows a 10-20 fold increase in an advanced invasive mammary tumor 
microenvironment. This increase in stiffness greatly influences cell behavior and 
facilitates tumor progression [51]. Furthermore, increased collagen crosslinking has 
been shown to lead to enhanced acquisition of malignant features [43]. Elevated 
expression of lysil-oxidase, an enzyme necessary for natural collagen type I 
crosslinking has been linked to increased fibrillar collagen deposition and linearization. 
Levental et al. demonstrated that ECM stiffness increases from normal to tumor. 
Strikingly, the stiffness of the tumor adjacent stroma was shown to be elevated in 
conjunction with the above-mentioned increases in levels of the crosslinker and 
linearization of collagen. Mammary epithelial cells grown within 3-D environments at 
physiological Young modulus (E values of 160–170 Pa) form small growth-arrested 
colonies with polarized β4-integrin and apical-lateral cortical actin, which are all 
features found in normal mammary epithelium [52]. By contrast, a small increase in 
stiffness (400 Pa) promoted the formation of double-sized colonies while further 
increases in matrix stiffness, closer to those exhibit by tumor-associated ECM, 
stimulated the formation of greater colonies with atypical (tumorigenic) acini structures 
and altered integrin and actin polarization [52]. Increased matrix stiffness generates the 
tension necessary to cluster α5β1-integrin in cell–matrix adhesions, thus facilitating cell 
migration and invasion. Furthermore, stiffness experienced by cells during adhesion to a 
substrate modulates intracellular mechanisms from gene expression to cell movement 
through integrin clustering and phosphorylation of integrin-regulated effectors, such as 
non-receptor tyrosine kinase like focal adhesion kinase (FAK) and p130Crk-assosicated 
substrate [43]. It has been demonstrated that results from cell culture experiments 
carried out on a 2-D rigid substrate such as tissue culture plastic may not be comparable 
to those obtained under in vivo conditions [53]. For instance, the stiffness of the ECM 
can regulate epithelial cell growth, differentiation, and migration, and reduction of ECM 
stiffness can suppress the malignant behavior of mammary epithelial cells [51]. Thus, 
the typical 2-D culture not only lacks the unique chemical and physical properties that 
modulate cell-cell interactions, but also influence the morphology of the individual cell 
unit. 
Mechancial stimuli are also very important in tissue engineering. Different 
types of mechanical stresses are experienced by various tissues. In vitro systems have 
been developed to model the effect of hydrostatic pressure or fluid shear stress on ECs, 
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and cyclic strain or compressive stress on chondrocytes. For instance, Dewey et al. 
demonstrated that confluent monolayers of ECs undergo a time-dependent change in 
cell shape from polygonal to ellipsoidal and become uniformly oriented under a laminar 
shear stress of 5-10 dynes/cm2 [54]. Obi et al. reported that fluid shear stress induces 
differentiation of circulating endothelial progenitor cells [55]. Using mouse embryonic 
stem cells differentiated in vitro, Adamo et al. showed that fluid shear stress increases 
the expression of Runx1 in CD41(+)c-Kit(+) haematopoietic progenitor cells, 
concomitantly augmenting their haematopoietic colony-forming potential, that increases 
with an increase in shear stress in vitro [56]. To stimulate chondrocytes, Mizuno et al 
demonstrated that cyclic hydrostatic fluid pressure that mimics the biophysical stimuli 
in the joints enhances matrix synthesis and accumulation by bovine chondrocytes in 3-D 
collagen scaffold biomaterials in vitro [57]. When a force is experienced by cells, the 
cells sense the microenvironmental cues and transmit the mechanical signal to 
intracellular biochemical signals via signal transduction. Several cellular 
mechanosensors, such as integrins and ion channels have been implicated [58]. For 
instance, integrins allow for a direct mechanical connection between the cell 
cytoskeleton and ECM, transmitting forces from the outside to the inside of the cell [59]. 
Such stimuli influence the cytoskeleton assembly directly, thereby translating the 
mechanical signal into changes in biochemical signaling pathways [60].  
 
2.2 Design of polymeric scaffold biomaterials 
To encourage cells to create their own ECM microenvironments, scaffold 
biomaterials should meet several requirements in terms of structural properties, bulk 
properties, and biological properties [61]. A major structural issue is to create 
interconnected pore structures that allow cells to migrate homogeneously into scaffold 
biomaterials. Moreover, a large surface area and space in the scaffold biomaterial 
enables cells to attach, grow, and produce their own ECM microenvironments. An 
optimal pore size ranging between 100 and 500 µm is necessary for cell migration and 
vascularization [62, 63]. Several technologies and methodologies have been developed 
to create highly porous scaffold biomaterials. Among them freeze-drying and porogen 
leaching [64] have been widely used to generate porous structures. Another 
sophisticated technologies include rapid prototyping and electrospinning that can create 
a defined structure of micropatterns and nanofibers, respectively [65-68]. However, at 
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present, it is practically difficult to fabricate a stable 3-D micropattern or a thick porous 
nanofiber in scaffold biomaterials.  
The mechanical property and biodegradability greatly affect the bulk property 
of scaffold biomaterials and subsequent tissue formation. Scaffold biomaterials should 
have excellent mechanical properties and remain for a certain period of time to keep a 
space for cells therein. Otherwise, the remaining material may impair the tissue 
formation. Several biodegradable polymers have been extensively utilized as 
biomaterials for scaffold fabrication [69]. Among them polyglycolide (PGA) and its 
copolymers, such as lactide–glycolide copolymer (PLGA), have been widely employed 
in many studies on tissue engineering. However, they degrade very quickly when used 
as a scaffold biomaterial. In contrast, poly(L-lactide) (PLLA) degrades extremely 
slowly (3–6 years) [61]. These synthetic polymers degrade through non-enzymatic 
hydrolysis, whereas natural polymers, including collagen, gelatin, and hyaluronic acid, 
undergo enzymatic hydrolysis. In general, most of natural polymers are hydrophilic and 
yield scaffold biomaterials with low mechanical strength in comparison with PGA, 
PLGA, and PLLA. Alginates do not contain any hydrolysable bonds, but are often used 
as a resorbable biomaterial when decomposed to a form with a smaller molecular 
weight enough to be excreted from the body [70, 71]. Water-soluble polymers are 
mostly rendered water-insoluble through covalent crosslinking. For instance, poly 
(ethylene glycol) (PEG) diacrylate has been widely used by crosslinking with 
thiol-group-containing enzyme sensitive peptides [20, 72, 73]. The thiol group was 
coupled with an acrylate group through the Michael reaction under a mild condition, 
which allows us to incorporate cells in the resulting PEG hydrogels. Several peptides 
with functional moieties, such as a protease cleavable peptide and a ECM binding 
peptide, have been employed to prepare cell-encapsulating PEG-based hydrogels with 
bioactivities [20]. 
Since the bulk property of the living tissue is extremely complicated to be 
mimicked using conventional biomaterials, biomolecules with high bioactivities, such 
as signaling molecules and ECM, have been utilized to improve biological properties of 
scaffold biomaterials and facilitate tissue formation [61]. There are two methods to 
combine biomolecules with scaffold biomaterials. One is the controlled release of 
biomolecules from scaffold biomaterials. The other is the surface modification of 
scaffold biomaterials with biomolecules, such as graft polymerization, micropatterning, 
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and protein coating or immobilization, that allows us to change the surface property 
including wettability, electric charge, morphology or roughness, and bioactivity [74]. 
Upon seeding onto the scaffold biomaterial with an appropriate surface property, cells 
could produce their own microenvironments and eventually form new tissues [75]. In 
the living system, cells receive external cues from the microenvironment through the 
interactions of cell-ECM, cell-cell, and cell-soluble factor, which are mediated by cell 
adhesion molecules, cell signaling molecules, and growth factors, respectively. 
However, since the biomolecules act upon receptors presented on cells in a highly 
sophisticated manner, people cannot always expect the bioactivities of the biomolecules 
outside the living system. Considering the biomolecules mainly made up of proteins, the 
immobilization of the proteins on biomaterial surfaces has been investigated as artificial 
microenvironments to achieve desired cellular functions for tissue regeneration [76]. 
Several covalent and non-covalent bonding methods, such as tethering with PEG 
[77-79], complexing with natural polymers [80-83], and fusion protein engineering of 
growth factor and different tagged molecules [84-90], have been investigated as a 
means to mimic cellular microenvironments through protein immobilization without 
losing the bioactivities for the induction of tissue regeneration. 
 
3. Enhanced neovascularization in scaffold biomaterials 
Another big issue of scaffold biomaterials is the neovascularization that is 
essential to supply nutrients and oxygen to the cells for tissue regeneration or to 
elucidate the distribution of nanoparticles in tissue engineering constructs for 
nano-pathophysiological researches. Neovascularization can be obtained by three 
approaches using angiogenic genes, angiogenic factors, and progenitor or stem cells 
[91-95]. Several attempts have been made to fabricate vascularized tissue engineered 
constructs in vitro [91, 92]. By contrast, in vivo neovascularization will be expected if 
the tissue engineered construct can provide adequate stimuli to the surrounding tissues. 
Neovascularization is the formation of vasculature in an avascular tissue. The formation 
of vasculature is based on two underlying mechanisms: angiogenesis and 
vasculogenesis. The basic idea of angiogenesis is the formations of new blood vessels 
from pre-existing ones by sprouting of capillaries. Vasculogenesis denotes the de novo 
assemble of ECs to capillaries in situ and regulates the first primitive vessel formation 
in early embryonic development. In this process, endothelial progenitor cells (EPCs) 
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migrate to avascular areas and differentiate to mature ECs in response to local cues, 
such as angiogenic factors and ECM, resulting in creating first primitive vessel 
networks [96]. Once the primitive vessel network formed, new blood capillaries emerge 
from the pre-existing vessels and generate more complex capillary networks, which are 
governed by angiogenic factors secreted from ECs and stromal cells, and/or cancer cells. 
To introduce vascular networks into tissue engineered constructs, similar processes are 
required (Figure 1).  
 
3.1. Angiogenic factors to enhance neovascularization 
 Angiogenic factors, such as vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF), have been utilized to promote neovascularization [97]. 
The VEGF family has been most widely investigated as one of the crucial modulators 
involved in several steps of neovascularization [98]. In some clinical trials, significant 
neovascularization and increased blood perfusion were observed [99, 100]. FGF 
functions not only as an angiogenic factor but also as a regulatory factor to maintain the 
integrity of vasculatures [101]. Among the FGF family, FGF-1 and FGF-2 have been 
extensively studied and utilized in therapeutic angiogenesis. FGF-1 gene therapy has 
been conducted using FGF-1-expressing plasmid DNA and showed the safety of 
angiogenic gene therapy in Phase I/II trials for patients with critical limb ischemia [102], 
while Phase II trial failed to demonstrate its benefit. Besides VEGF and FGF, 
hepatocyte growth factor (HGF) and platelet-derived growth factor (PDGF)-BB have 
also been studied. It has been shown that HGF stimulates ECs proliferation via VEGF 
production, and promotes secretion of proteases to be involved in ECM degradation and 
cell migration [103]. PDGF-BB promotes FGF-2 release and FGF receptor activation in 
vascular smooth muscle cells [104], and plays an important role in maturation of 
vasculature [105]. Another cytokines or chemokines, such as granulocyte 
colony-stimulating factor (G-CSF), stroma cell-derived factor (SDF)-1, and substance P, 
are also known to contribute to neovascularization by mobilizing progenitor cells or 
neutrophil granulocytes from bone marrow and subsequently recruiting the cells to the 
site of angiogenesis [93].  
In the in vivo system, most of angiogenic factors exist in an inactive form by 
binding to ECM components, such as proteoglycan, collagen, and fibrin [106], and with 
the onset of angiogenesis, their active form will be released from ECM through 
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enzymatic activations. Therefore, regardless of the factor type, it is necessary to develop 
a delivery system that can realize stable concentration of the angiogenic factor suitable 
for inducing neovascularization in vivo. Although prolonged expression of an 
angiogenic gene could expect a higher local concentration of the resulting protein 
enough to induce angiogenesis, protein administration may be more predictable in terms 
of initial dose and pharmacokinetics of the angiogenic factor than the genetic approach. 
Several controlled release system comprises hydrogels, microspheres, porous scaffolds, 
and nanofibers, and both natural and synthetic polymers have been explored to enhance 
biological activities of angiogenic factors (Table 2) [92, 95]. Among natural polymers, 
fibrin, collagen, gelatin, alginate, and hyaluronic acid are widely investigated. 
Angiogenic factors have been incorporated into fibrin matrices together with heparin, 
leading to better control of the release rate of heparin-binding growth factors, such as 
FGF-2, than fibrin matrices alone [107]. Hubbell et al. created a fibrin-binding VEGF 
fusion protein via recombinant protein engineering that enables the introduction of a 
specific binding domain into growth factors at a desired location not to lose their 
bioactivities [108]. The fibrin-binding VEGF fusion protein allows VEGF to be released 
in a controlled manner via proteolysis for the matrix remodeling after ECs infiltration.  
Marui et al. reported that the dual release of a lower dose of FGF-2 and HGF 
from the collagen microspheres could achieve equivalent blood perfusion recovery and 
more mature vasculature in ischemic limbs than a higher dose of FGF-2 or HGF alone 
[109]. To improve the affinity of growth factors to collagen [110], heparin was 
covalently introduced into collagen-based scaffold biomaterials [111]. Similar to the 
fibrin-binding VEGF fusion protein, a collagen-binding VEGF fusion protein 
demonstrated better retention in collagen-based scaffold biomaterials compared with 
VEGF alone, and showed the promoted angiogenesis in the ischemic heart [112, 113]. 
Tabata et al. demonstrated the effectiveness of FGF-2 protein released from 
gelatin hydrogels in various animal models either non-diabetic or diabetic for acute 
myocardial infarction [114, 115], prevascularization for cardiomyocyte transplantation 
to the ischemic heart [116], limb ischemia [117], and bone regeneration [118]. 
Furthermore, Marui et al. have shown the safety and feasibility of the controlled release 
system in patients with critical limb ischemia, who had no option of medical or surgical 
treatment [119]. 
We utilized an alginate hydrogel patch to deliver SDF-1 and demonstrated the 
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accelerating healing and reducing scarring in an animal model that closely mimics 
human wound healing using Yorkshire pigs with acute surgical wounds (Figure 2) 
[120]. Alginate microspheres can also be employed for controlled release of entrapped 
proteins. Protein loss during microsphere fabrication has been a major drawback for 
application as a controlled release system [92]. On the other hand, a hyaluronic acid 
hydrogel conjugated with cell adhesion peptides and matrix metalloproteinase-cleavable 
peptides to entrap angiogenic factors and endothelial colony-forming cells. By using the 
hyaluronic acid hydrogel with angiogenic activities, Hanjaya-Putra et al. showed that a 
functional vascular network forms in situ and integrates with the host vasculature [121]. 
 Synthetic polymers, such as PGA, PLA, and their copolymer [122-129], and 
PEG derivatives [130-132], have been investigated as controlled release systems for 
angiogenic growth factors. To avoid the bioactivity loss caused by exposure to organic 
solvents in fabrication processes, many researches have employed heparin for controlled 
release systems of angiogenic growth factors from PLGA [126]. Combination of an 
angiogenic factor-encapsulating PLGA microspheres with another angiogenic 
factor-incorporating porous PLGA scaffolds achieves sequential angiogenic factor 
delivery, such as VEGF and Angiopoietin-I [127], VEGF and PDGF-BB [128], or 
FGF-2 and PDGF-BB [129], to promote more mature and stable vessel formation than 
simultaneous delivery of the angiogenic factors.  
Hubbell et al. fabricated PEG hydrogels by crosslinking with cleavable 
linkers, such as matrix metalloproteinase-cleavable peptides, and demonstrated the 
cell-demanded release of VEGF and the subsequent cell ingrowth into the PEG 
hydrogel [130]. West et al. introduced a VEGF-mimetic peptide, a cell adhesion peptide 
of Arg-Gly-Asp, and a collagenase-cleavable peptide into PEG diacrylate hydrogels 
using a succinimidyl ester linker and showed the promoted angiogenesis into the 
hydrogel [131]. Salimath et al. reported the dual delivery of HGF and VEGF from a 
protease-degradable PEG hydrogel could improve cardiac function in rat with acute 
myocardial infarction caused by ischemia and reperfusion [132]. Werner et al. 
demonstrated that a local concentration gradient of SDF-1 generated by PEG hydrogels 
containing a sulfated-glycosaminoglycan could enhance the recruitment of circulating 
EPCs and subsequent angiogenesis in vivo [133].  
  
3.2. Angiogenic cells to enhance neovascularization 
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Cell source is also an important topic for enhanced neovascularization. 
Primary sources are ECs that include human dermal microvascular ECs (HDMECs), 
human umbilical vein ECs (HUVECs), bovine aortic ECs (BAECs), and bovine 
capillary ECs (BCEs). Furthermore, Jarrell et al. have used microvessel endothelium 
isolated from a liposuction-derived fatty tissue through a Percoll density gradient [134]. 
However, the complicated isolation protocol and low proliferation rates for autologous 
ECs may become a major drawback to their application. Therefore, EPCs from various 
adult sources, such as umbilical cord blood, peripheral blood, bone marrow-derived 
mononuclear cells, and fat tissue, have been proposed as an alternative cell source for 
neovascularization.  
Asahara and Isner identified EPCs in 1997 and described their role in 
vasculogenesis for hind limb ischemia [135]. EPCs can differentiate into mature ECs as 
verified by endothelial markers, such as von Willebrand factor (vWF), platelet 
endothelial cell adhesion molecule-1 (PECAM-1/CD31), and vascular 
endothelial-cadherin (VE-Cad) [136]. EPCs have the potential to migrate and 
incorporate into ischemic tissue, and blood flow recovery and capillary density were 
significantly improved after EPC transplantation in animals [137]. As a result, EPCs 
reduced the rate of limb loss and increased blood flow in diabetic mice with impaired 
circulation [138]. They also improved neovascularization and myocardial function in 
mouse cardiac infarction models [139]. These findings suggest that exogenously 
administered EPCs augment neovascularization based on the cross talk between EPCs 
and other cell types mediated by angiogenic factors or cell-cell interactions. 
Systemically administering granulocyte macrophage-colony stimulating factor 
(GM-CSF) increased the circulating EPC population and augmented neovascularization 
of ischemic tissues [140]. VEGF increased mobilization of EPCs in peripheral blood of 
mice. Other mobilizing factors include angiopoietin-1 (Ang-1), placental growth factor 
(PlGF), and erythropoietin. Mobilizing factor release plays a crucial role in recruiting 
EPCs to sites of neovascularization. Another important recruitment factor is SDF-1. 
SDF-1 binds to the chemokine receptor CXCR-4, which is highly expressed on EPCs in 
addition to bone marrow stroma. Once sites of neovascularization are reached, EPCs 
may recruit additional EPCs by releasing growth factors, such as VEGF, HGF, G-CSF, 
and GM-CSF.  
EPCs have been demonstrated to differentiate towards ECs in culture both 
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with and without VEGF [141-143]. Because of their angiogenic potential, EPCs have 
been utilized not only for therapeutic intervention in ischemic diseases but also for 
endothelialization of implants, such as vascular grafts and stents [144, 145]. Moreover, 
engraftment of EPCs is an attractive possibility for enhanced neovascularization in 
scaffold biomaterials. EPCs accelerated the vascularization of heparin-immobilized 
PCL scaffold biomaterials in the presence of VEGF [146]. It has been shown that the 
co-culture of EPCs with different cell types, such as smooth muscle cells, fibroblasts, 
adipocytes, or osteoblasts, plays a crucial role in supporting angiogenesis [147-150]. 
The presence of EPCs enhanced dermal vascularization with capillary-like structures 
homogeneously in scaffold biomaterials [151]. The integrative use of bioreactor culture 
systems and co-cultured osteogenic cells and EPCs promotes maturation of vascularized 
bone tissue engineered constructs in vitro [152].  
In contrast to normal tissues, the vasculature of solid tumors has a limited 
diffusion, resulting in the tissue hypoxia with a low oxygen concentration. This tissue 
hypoxia triggers a cascade of hypoxia-inducible factor-1 (HIF-1) and VEGF-mediated 
signaling events that initiate tumor neovascularization. Hida et al. demonstrated that 
ECs in solid tumors are cytogenetically abnormal and aneuploid with multiple 
chromosomes and multiple centrosomes [153, 154]. Unlike normal ECs, which remain 
diploid in long-term culture, the aneuploidy of tumor ECs increases in culture 
suggesting that these cells are inherently unstable. Moreover, tumor ECs show 
resistance to paclitaxel compared with normal ECs [155]. Taken together, it is likely 
that heterogeneity of ECs with different phenotypes needs to be concerned in 
mimicking a pathological endothelium in vascularized tissue engineered constructs. 
However, a source of viable and stable ECs in vitro is a major challenging. One possible 
way to tackle this issue is to use embryonic stem cells (ESCs) or induced pluripotent 
cells (iPSCs). We have recently demonstrated the ability of hESCs to self-renew and to 
generate ECs [156, 157]. In addition to their self-renewal capacity, hESCs have the 
potential for large-scale differentiation into any adult cell types in vitro, and are thus an 
attractive alternative source of ECs. The emergence of ECs from differentiating hESCs 
could be monitored by an EC-specific genetic reporter, whereby the VE-Cad promoter 
drives expression of green fluorescent protein (hVPr-GFP). This novel approach for 
vascular monitoring in combination with the ability to grow cells on 3-D scaffold 
biomaterials will allow us to examine the contribution of the hVPr-GFP positive ECs to 
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the neovascularization process in tumors. 
 
4. Vascularized tissue engineering constructs for nano-pathophysiology 
Substantial efforts have already been made to understand angiogenic 
processes taking place in ischemic tissues and tumors. On the basis of the angiogenic 
process, different approaches have been attempted to introduce vascular networks in 
tissue engineered constructs (Figure 1.). Two strategies have been proposed to create 
vascularized tissue engineered constructs. The first is “Top down approach” based on 
the ECs and their ability to form vascular networks in vivo. The second strategy of 
“Bottom-up approach” deals with the vessels themselves in vitro. 
 
4.1. Top-down approaches (in vivo) 
 Enhanced neovascularization in vivo aims to create vascular networks for 
following cell transplantation or to connect host vasculatures with prefabricated in vitro 
vascular networks in tissue engineered constructs. The newly formed vascular network 
could be expected to supply nutrients and oxygen for cells enough to survive and 
function in vivo. To build a functional vascular network for tissue engineered constructs, 
two approaches have been developed. One is to utilize controlled release systems of 
angiogenic factors for neovascularization. Arteriovenous (AV) loops are the other 
neovascularization approach to generate vascularized tissue engineered constructs in 
vivo. Angiogenic factors could enhance neovascularization based on their bioactivities, 
that stimulate ECs or EPCs to migrate towards the factor gradient and subsequently 
promote cell assembly, vessel formation, and maturation. The controlled release 
systems as described above have been used with or without scaffold biomaterials. To 
induce neovascularization in scaffold biomaterials, the physical parameters are critical. 
Specifically, pore size has been evaluated in a mouse ectopic implantation model using 
poly(vinyl alcohol) porous scaffold biomaterials combined with a controlled release 
system of FGF-2. A pore size above 250 µm was necessary for vascular ingrowth into 
the scaffold biomaterial [63]. This area of research remains critical with unexplored 
issues of microenvironment contribution to vascularization of tissue engineered 
constructs. Neovascularization in vivo prior to cell transplantation enables cells to 
survive and function even in ischemic sites [116]. For instance, Sakakibara et al. 
reported that neovascularization induced by the controlled release of FGF-2 enables 
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transplanted cardiomyocytes to improve the left ventricular function in rats with 
myocardial infarction [158]. Furthermore, using the same controlled release system, Gu 
et al. demonstrated that combination of gelatin microspheres incorporating FGF-2 and 
collagen scaffolds allows the xenogeneic islets-containing bioartificial pancreas devise 
to induce neovascularization even at the subcutaneous site of streptozotocin-induced 
diabetic rats, resulting in improved function of islet transplantation [158]. One 
disadvantage of this neovascularization approach is the lack of reproducibility and 
standardization in terms of the structure of the resulting vascular network. 
By contrast, AV loops enables us to fabricate vascularized tissue engineered 
constructs with capillaries of artery and vein in a controlled fashion. The resulting AV 
roop can be utilized to connect with host vessels by suturing under a surgical 
microscope [159-164]. To obtain such a functional vascular network, a scaffold or 
chamber is placed within an AV loop in a site of rich vascularization in vivo, mainly 
muscle. After the formation of an artery-capillary-vein network by the surrounding 
tissue, the construct can be transferred to the reconstructive defect [165]. Mian et al 
reported that an isolated chamber is capable to generate new vascularized tissue even in 
the absence of added ECM [163]. Polykandriotis et al. performed the AV loops for 
neovascularization of bovine cancellous bone matrix to obtain vascularized hard-tissue 
constructs [166]. The application of the AV loop provides a promising tool for 
fabrication of vascularized tissue engineered constructs.  
 
4.2. Bottom-up approaches (in vitro) 
Unlike the “Top-down approaches”, the 3-D positioning of cells together with 
angiogenic cells in vitro could recreate physiological or pathological vasculatures in a 
controlled fashion in terms of structures and cell types. This reproducibility and 
standardization in fabricating vascularized tissue engineered constructs in vitro is a 
major advantage of “Bottom-up approaches”. The controlled assembly of different 
vascular cells, such as ECs and pericytes, could realize vascularized tissue engineered 
constructs with particular vascular structures seen in pathological tissues, and 
quantitatively recapitulate the in vivo dynamic behavior of nanoparticles in in vitro 
conditions. Unlike conventional animal models, the vascularized tissue engineered 
construct connected with host vasculatures will function as an alternative experimental 
platform with a higher reproducibility and quantitativity even in the in vivo conditions. 
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However, building a natural connection of the engineered vascular network with the 
existing host vasculature, a process called anastomose, is a major issue to be challenged. 
Although the difficulty in anastomosis requires numerous investigations both through in 
vitro and in vivo approaches, there still remain some substantial challenges to develop 
technologies for rebuilding vascular networks in tissue engineered constructs [91, 92].  
Recently two different strategies have been proposed to rebuild vascular 
networks in tissue engineered constructs in vitro. The first strategy is to fabricate 
synthetically vascularized scaffold biomaterials. Decellularization of tissues and organs 
is the second strategy termed biologically vascularized scaffold biomaterials, that 
maintain intact 3-D geometry, vasculature, and ECM structure. Effective 
neovascularization in tissue engineered constructs is inherently linked to intelligent 
design and sophisticated fabrication for scaffold biomaterials. Smart 3-D design and 
high resolution manufacturing technologies are used to define cell alignment and 
angiogenesis. Several technologies, such as sacrificial templates [167, 168], 
microfluidics [169-171], organ printing [172-174], and 3-D scaffold biomaterials [175, 
176], have been developed.  
Chen et al. developed a technique that can print rigid 3-D filament networks 
of carbohydrate glass, and used them as a cytocompatible sacrificial template in tissue 
engineered constructs containing living cells, such as primary rat hepatocytes [167]. 
Yoshida et al. used silica tubes as a sacrificial template to reconstruct a bilayered vessel 
structure consisting of a monolayer of ECs and surrounding smooth muscle cells in 
vitro [168]. Using the sacrificial templates allows independent control of network 
geometry, endothelialization, and extravascular tissue, and is compatible with a wide 
variety of cell types, and synthetic and natural scaffold biomaterials.  
On the basis of a microfluidic technique, Zheng et al. fabricated living 
microvascular networks in 3-D tissue engineered constructs and demonstrated their 
biofunctionality in vitro [169]. The endothelialized microfluidic vessels within a native 
collagen matrix recapitulate endothelial characters in terms of the morphology, mass 
transfer processes, long-term stability of the endothelium, angiogenic activities, and 
nonthrombotic nature. Another approach is to combine vascularized native tissues with 
a microfluidic perfusable bioreactor [170]. In this approach, triple-layer cardiac cell 
sheets produced from co-culture with ECs were placed on resected tissue with a 
connectable artery and vein as a vascular bed and were maintained in a media perfused 
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bioreactor. As a result, ECs connect to capillaries in the vascular bed and form tubular 
lumens, creating in vitro cardiac tissues with vascular networks to be transplanted with 
blood vessel anastomoses. Beside the resected tissue, Shimizu et al. also used a 
perfusion bioreactor having collagen-based microchannels [171]. When triple-layer 
cardiac cell sheets are incubated within this bioreactor, ECs in the cell sheets migrate to 
vascularize in the collagen gel, and finally connect with the microchannels.  
Bioprinter technique could use computer-aided design (CAD) data sets to 
realize freeform 3-D printing [172-174]. Tissue engineered constructs, built by those 
layer-by-layer manufacturing processes, can match the in vivo characteristics of porosity, 
mechanical strength and vascularization, with the correct spatial positioning and 
morphology. Xu et al. fabricated functional 3-D tissue engineered contractile cardiac 
hybrids by arranging alternate layers of biocompatible alginate hydrogels and 
mammalian cardiac cells according to pre-designed 3-D patterns [174]. 
Fischbach et al. engineered 3-D human tumor models using carcinoma cells in 
polymeric scaffold biomaterials that recreated microenvironmental characteristics 
representative of tumors in vivo [175]. Interestingly, the angiogenic characteristics of 
tumor cells were dramatically altered upon 3-D culture within this system, and 
corresponded much more closely to tumors formed in vivo. We have recently succeeded 
in generating stable cultures of vascularized cells in a honeycomb alginate scaffold 
biomaterials self-organized into capillary-like structures with an average channel 
diameter of 300 µm (Figure 3) [176]. The porous 3-D alginate depots containing cells, 
in a serum-free condition, were further exposed to laminar flow to recapitulate the 
vasculature in vivo. The scaffold biomaterial remained intact with the cells remaining 
adhered to it and aligned in the direction of flow, demonstrating its suitability for 
establishing durable angiogenic modules that may ultimately enhance organ 
revascularization or model tumor neoangiogenesis. 
Despite the recent progress in the development of the synthetic vascularized 
scaffold biomaterials, mimicking and rebuilding natural vasculatures in vitro is still 
challenging. Therefore, the reuse of biological vascular structures by decellularizing 
tissues and organs is an alternative approach to tackle this problem. This decellularized 
tissue and organ are designated as “biologically vascularized scaffold biomaterials” that 
maintain intact 3-D geometry, vasculature, and ECM structure. Several organs, such as 
heart [177], lung [178], liver [179], kidney [180], and small intestinal submucosa [181], 
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have been proved to hold promising performances after decellularization and 
subsequent repopulation with functional cells including ECs. For example, the 
decellularization and the repopulation with neonatal cardiac or aortic ECs of rat hearts 
as well as the culture under simulated physiological conditions led to the formation of 
contractile myocardium [177]. Indeed, this biologically vascularized scaffold 
biomaterial provides some advantages including physiological or pathological vascular 
perfusion, biocompatible ECM structures, and relevant geometries for cell positioning. 
However, a major limitation of this approach is the lack of the standardization and 
reproducibility in 3-D structures due to the animal-derived material. Therefore, 
combination of a defined 3-D geometry based on natural tissue and organ structures and 
decellularized ECM components will open up a new generation of synthetic 




 Scaffold biomaterials are used in a variety of tissue engineering and drug 
delivery purposes to promote angiogenesis, and hence influence the regeneration of 
tissues and organs in the body. Cellular interactions with their environment are of 
central importance to many biological processes and are important in the context of 
tissue engineering and regenerative medicine. Several approaches such as sacrificial 
templates, microfluidics, organ printing, and 3-D scaffold biomaterials, will enable one 
to grow, or engineer, long-lasting tissues and organs using 3-D depots, which may serve 
to guide new tissue formation therapeutically in the body or in vitro as relevant models 
to study disease nano-pathophysiology. Insights gained from 3-D platforms may 
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Figure 1.  Schematic drawing of two strategies to create vascularized tissue 
engineered constructs. The first is “top down approach” based on the ECs and their 
ability to form vascular networks in vivo. The second strategy, “bottom-up approach”, 
deals with the vessels themselves in vitro. 
 
Figure 2.   SDF-1 treatment accelerates healing of acute surgical wounds. (A) Percent 
cumulative release of SDF-1 in vivo. (B) Percent wound healing over time shown for 
SDF-1 protein ( ) treated wounds and nontreated sham ( ) or saline ( ) in a porcine 
model of acute dermal wound closure.  
 
Figure 3.   A representative image of alginate scaffolds and GFP-labeled HUVECs in 
the scaffolds obtained by scanning electron microscope and confocal microscope. (A–
C). Alginate scaffolds with aligned-pore structure. Average pore diameter is 352 mm 
and porosity is 93.7%. (A) Horizontal images and (B) vertical images of scaffolds. 
Magnification of each image is 10x. In addition, Z-stack images were taken after 1 day 
of cell seeding at a magnification of 10x and reconstructed through a projection mode 
using LSM510 software. 
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Table 1. ECM proteins with a tumor-specific modification	
ECM proteins	 Tumor-specific modifications	 Distribution or function	 References	
tenascin-C	 full-length unspliced isoforms	 pancreatic and prostate cancer	 [37, 42]	
isoform containing domain C	 gliomas	 [35]	
isoform containing domain A and D	 breast and ovarian carcinoma	 [34, 38] 	
fibronectin	 FN-extradomain (ED)A	 conversion fibroblasts to myofibroblasts	 [45]	
FN-EDB	 seen in neovascular structures in many 
different tumor types	
[36, 40]	
collagen and elastin	 crosslinked with lysyl oxidase (LOX)	 elevated ECM stiffness	 [43]	
Table 2. Controlled release systems for angiogenic factors	
Origin	 Materials	 Forms	
Natural polymer	 fibrin hydrogel, sponge 
collagen	 hydrogel, microsphere, sponge	
gelatin	 hydrogel, microsphere, sponge	
alginate	 hydrogel, microsphere, sponge	
hyaluronic acid hydrogel	
chitosan	 microsphere	
Synthetic polymer	 lactide–glycolide copolymer (PLGA) 	 microsphere, sponge	
polycaprolactone (PCL) 	 sponge, nanofiber	
poly(ethylene glycol)	 hydrogel	
